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Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the
frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any
long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased
drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely
recommended in preterm neonates. However, a better understanding of the genetic background of each infant
may allow for individualized prophylaxis using NSAIDs and metabolomics.
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INTRODUCTION
Botallo’s duct is a blood vessel that connects the
pulmonary artery to the aorta during fetal development,
and our knowledge of the pathophysiology of this duct is
increasing steadily.1
Clinically, ‘patent DA’ (ductus arteriosus) is often used
synonymously with ‘persistent DA’, and both are frequently
abbreviated as ‘PDA’ even though they differ in morphol-
ogy and therapeutic implications.2,3 The term ‘patent DA’ is
an umbrella term that is used for all situations in which the
DA is either physiologically or pathologically open. In this
review, we will use the abbreviation ‘PDA’ to refer to patent
ductus arteriosus.
A patent ductus arteriosus (PDA) is a physiologic shunt in
healthy full-term and preterm infants that tipically presents
during the first three days of life.4
PDA in preterm infants may have clinical consequences
depending on the degree of left-to-right shunting. The increase
in pulmonary blood flow in premature infants may lead to
pulmonary edema, loss of lung compliance, and deterioration
of the respiratory status, which ultimately lead to chronic lung
disease (CLD) and an increased morbidity and mortality.5
A shunting of blood between the aorta and pulmonary
artery, which is favored by the postnatal decrease in
pulmonary vascular resistance,6 causes the hemodynamic
and clinical consequences of PDA. The shunt also modifies
the distribution of blood to the lungs and other organs and
may contribute to an increased risk of serious and
prolonged neonatal respiratory distress, intraventricular
hemorrhage (IVH), necrotizing enterocolitis (NEC), bronch-
opulmonary dysplasia (BPD), and death.7,8
The incidence of PDA in full-term neonates has been
estimated to be 57 per 100,000 live births,3 whereas
persistence of the duct occurs in approximately one-third
of premature neonates with a birth weight between 501 and
1,500 grams.9
In neonates weighing less than 1,000 g, it has been
reported that 55% develop a symptomatic PDA requiring
pharmacological treatment.10,11 The spontaneous closure of
a PDA takes place between the second and sixth day of life
in 34% of extremely low birth weight (ELBW) neonates12
and within the first year of life in the majority of very low
birth weight (VLBW) neonates.
Postnatal ductal closure is regulated by exposure to
oxygen and vasodilators. The ensuing vascular response,
which is mediated by potassium channels, voltage-gated
calcium channels, mitochondria-derived reactive oxygen
species, and endothelin 1, depends on the gestational age.
Platelets are recruited to the luminal surface of the DA
during closure and are hypothesized to promote the
thrombotic sealing of the constricted DA.13
It has been estimated that 60% to 70% of preterm infants
less than 28 gestational weeks receive medical or surgical
therapy for a PDA, usually with the intention to prevent
respiratory decompensation, heart failure, IVH/brain
injury, BPD, NEC, and death.14,15
The natural history of PDA in premature infants remains
unknown, and its management is highly controversial. The
following four strategies are most often used in the
treatment of PDA: 1) symptomatic treatment when the duct
is deemed hemodynamically relevant by clinical or ultra-
sonographic evaluation;16 2) targeted treatment of ducts
echocardiographically detected in the first 24 hours of life
but before a significant left-right shunt has developed;17 3)
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conservative management with only ventilation adjust-
ments and fluid restriction; 4) a prophylactic approach,
which medically or surgically treats all neonates at risk for
PDA in the first 24 hours of life.18
Despite numerous studies, some controversies regarding
PDA prevention remains. The prophylactic use of indo-
methacin, whether the DA is patent or not, is the best-
studied regimen. The timing of this approach is important
(it is given very early, within the first 24 hours) because its
effectiveness clearly decreases with increasing postnatal
age; however, this treatment involves the risks associated
with exposing infants to drugs that they might not need.
Importantly, prophylactic trials can examine the associa-
tion between PDA and the incidence of IVH or pulmonary
hemorrhage, which typically occurs within the first
moments of life, whereas symptomatic trials cannot exam-
ine this relationship. Conversely, symptomatic trials can
examine the relationship between PDA and NEC, which
occurs later in postnatal life, whereas prophylactic trials
would be unlikely to do so.19,20
In this paper, we will only address the prophylactic
approach for PDA management.
PROPHYLACTIC USE OF INDOMETHACIN
Indomethacin is used prophylactically to close the PDA
before hemodynamic distress occurs, which has been
associated with an increased morbidity and mortality,
without the need for screening or echocardiographic
surveillance. This approach exposes a large number of
neonates, in whom the duct would close spontaneously, to a
pharmacologic treatment that is not without risk.
Intravenous indomethacin, a non-selective cyclooxygen-
ase inhibitor, is the standard pharmacological treatment for
PDA in preterm neonates and has a reported effectiveness
of 66–80%.21-23
Since the 1980s, several risk-benefit studies have been
conducted to evaluate the intravenous administration of
indomethacin for prophylactic treatment of PDA. The first
small, controlled, randomized trials suggested that early
prophylaxis (i.e., within the first 24 hours) with indometha-
cin reduced the incidence of serious IVH.
Interestingly, a significant increase in the use of indo-
methacin prophylaxis occurred after the Ment et al. trial was
published; however, a significant decrease in the use of
indomethacin prophylaxis followed the TIPP trial.24
In 1994, Ment et al.25 was the first to publish a
prospective, randomized, placebo-controlled trial to inves-
tigate whether low-dose indomethacin (0.1 mg/kg intrave-
nously at 6 to 12 postnatal hours and every 24 hours for two
more doses) would lower the incidence and severity of IVH.
The authors enrolled 431 neonates with a birth weight of
600 to 1,250 g and no evidence of IVH at 6 to 11 hours of
age. Serial cranial ultrasounds and echocardiograms were
performed. Within the first five days, 25 (12%) indometha-
cin-treated and 40 (18%) placebo-treated neonates devel-
oped IVH (p= 0.03, trend test). However, only one
indomethacin-treated patient experienced grade 4 IVH
versus 10 placebo-treated neonates (p= 0.01).
In 2001, Schmidt26 published the results of another large-
scale, controlled, randomized trial, the Trial of Indome-
thacin Prophylaxis in Preterm (TIPP), that evaluated the
long-term effects of indomethacin on motor, sensory and
cognitive outcomes.
In this study, 1,202 ELBW infants (500–999 g) were
randomly assigned to receive either indomethacin (0.1 mg
per kilogram of body weight) or placebo intravenously once
daily for three days soon after birth.
The primary outcomes investigated were death, cerebral
palsy, cognitive delay, deafness, and blindness at a
corrected age of 18 months. The secondary long-term
outcomes were hydrocephalus necessitating placement of
a shunt, seizure disorder, and microcephaly within the same
time frame. Secondary short-term outcomes were PDA,
pulmonary hemorrhage, chronic lung disease, ultrasono-
graphic evidence of intracranial abnormalities, necrotizing
enterocolitis, and retinopathy.
Of the 574 infants with primary outcome data who
received indomethacin prophylaxis, 271 (47%) died or
survived with impairments, as compared with 261 of the
569 infants (46%) assigned to placebo (odds ratio, 1.1; 95
percent confidence interval, 0.8 to 1.4; p= 0.61).
Indomethacin reduced the incidence of PDA (24% vs. 50% in
the placebo group; odds ratio, 0.3; p,0.001) and severe PVH
and IVH (9%, vs. 13% in the placebo group; odds ratio, 0.6;
p= 0.02). No other outcomes were altered by the prophylactic
administration of indomethacin. However, indomethacin
prophylaxis increased the need for supplemental oxygen from
day 3 to at least day 7 of life. Indomethacin also decreased the
urine volume during the first four days of life and reduced
weight loss by the end of the first week.
These papers concluded that in ELBW infants, indo-
methacin prophylaxis does not improve the survival rate
without neurosensory impairment at 18 months, despite the
fact that it reduces the frequency of PDA (NNT 4) and
severe PVH and IVH.
The reduction in IVH can be explained by the maturation
of the cerebral vascular basement membrane, improvement
in cerebrovascular self-regulation and anti-inflammatory
effects.27,28 More recent data detailing reduced germinal
matrix hemorrhaging via inhibition of angiogenesis indir-
ectly support this hypothesis.29
In a follow-up to the TIPP study, 999 ELBW were given
indomethacin prophylaxis. The treatment did not prevent
BPD, although it reduced the frequency of PDA.30
The frequency of CLD was higher, which may be
associated with the reduced weight loss, the greater need
for oxygen and perhaps the increase in extracellular liquid
at the pulmonary level.
Reducing the frequency of PDA may be important for
those children requiring surgical closure, although twenty
prophylactic treatments with indomethacin are required to
avoid surgical treatment.
In another follow-up to the TIPP study that was
continued up to 18 months of life, prophylactic indometha-
cin reduced the rate of early serious pulmonary hemorrhage
because of its effects on PDA. However, prophylactic
indomethacin was less effective in preventing serious
pulmonary hemorrhages that occur after the first week of
life.31 Currently, the main limitations of the TIPP trial are
methodological concerns, such as the use of composite
outcomes and a lack of statistical power.
Another important study was published by Vohr.32 Their
cohort consisted of 328 VLBW (birth weight of 600–1,250 g)
infants who were enrolled in a low-dose, prophylactic
indomethacin prevention trial and IVH negative at six
postnatal hours.
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The cohort was divided into the following four subgroups
for analysis: indomethacin plus IVH, indomethacin without
IVH, saline plus IVH, and saline without IVH. The children
were evaluated prospectively at eight years old. Children in
both IVH groups had more cerebral palsy and hearing
impairment as well as lower daily living skills scores, IQ
scores, and vocabulary, reading and mathematics achieve-
ment test scores. Additionally, these children had greater
educational resource needs. Logistic regression analyses
showed that grade 3 to 4 IVH, periventricular leukomalacia
and/or ventriculomegaly, male gender, maternal education,
and the language spoken at home contributed to the
outcomes. The authors concluded that although biological
factors contribute significantly to school-related outcomes in
VLBW survivors, social and environmental factors are also
important contributors. Importantly, no effects of indo-
methacin or gestational age were identified in this study.
Cordero et al.33 compared the clinical responses of ELBW
infants to indomethacin prophylaxis to that of other infants
who were managed with indomethacin or surgical treatment
only after a symptomatic PDA was detected. The study was a
retrospective cohort investigation of 167 ELBW infants who
received indomethacin prophylaxis (study) and 167 ELBW
infants treated after detecting a symptomatic PDA (control)
who were matched by year of birth (1999 to 2006), birth
weight, gestational age (GA) and gender. Indomethacin
prophylaxis did not show any advantages over early
treatment for managing a symptomatic PDA in ELBW infants.
The incidence of IVH was the same in the newborns receiving
indomethacin prophylaxis and those in the control group.
The use of indomethacin to prevent PDA has been
demonstrated to reduce the incidence of a symptomatic
duct, the need for surgical closure and the occurrence of
pulmonary hemorrhage.34,35 However, whether this reduc-
tion is significant has been controversial.36
A recent meta-analysis of 19 studies in Cochrane
(involving 2,872 preterm infants) that also included the
trials by Ment and Schmidt discussed above, confirmed that
prophylactic indomethacin has short-term benefits for
preterm infants, including a reduction in the incidence of
symptomatic PDA, the need for surgical PDA ligation, and
severe IVH. However, there was no evidence of its effect on
mortality or neurodevelopment.5
Four neonates must be treated to close one DA (i.e., four is
the number needed to treat) and twenty to avoid IVH. The
same number 20 is needed to avoid surgical closure and
pulmonary hemorrhage, and 25 are required to avoid a
periventricular leukomalacia. Unfortunately, there was no
effect on mortality or the long-term neurological outcomes.
However, prophylactic indomethacin does not reduce the
incidence of pneumothorax, the duration of ventilation, the
duration of oxygen therapy or the incidence of CLD (at 28
days or 36 weeks). CLD, brain injury and ROP were
predictive factors of late death or neurosensory impairment
in the follow-up to the TIPP study.37
There are recent data on the long-term alterations that are
observed at school age in preterm children who were
treated with indomethacin or saline.38,39 At 12 years of age,
those children who had received indomethacin prophylaxis
had an increased amount of gray matter in the left inferior
parietal lobe, which is responsible for phonologic processes.
Males had better phonological scores than saline-treated
males.40 Again, newborns given indomethacin prophylaxis
had greater parenchyma in the left lingual lobe at 8 years,
but there was no effect on reading. Finally, newborns given
indomethacin prophylaxis at birth had better connectivity
between specific areas of the two hemispheres (from the
right BA 40 and BA 44-45 to the left BA 22). However,
indomethacin did not affect the intellectual function of
children who were born preterm.41,42
The only major side effect of indomethacin reported in the
2010 Cochrane review was the increased incidence of
oliguria, but it was not associated with any documented
kidney damage. In the same review, no differences in the
incidence of NEC or excessive bleeding were demonstrated.
However, there were several side effects following the use
of indomethacin demonstrated that raise serious concerns,
including a reduction in cerebral blood flow,27,43,44 the
volume of blood delivered to the brain and the release of
brain tissue oxygen;45 oliguria and transitory kidney
insufficiency;46,21-23 necrotizing enterocolitis; isolated intest-
inal perforation; and gastrointestinal hemorrhage.21,47
It is important to note that administering furosemide
before each indomethacin dose resulted in a significant
increase in the serum creatinine level and hyponatremia
without increasing urine output.48
Although most of the included studies were high quality,
the drug dosage varied from one study to another, and the
patient population was not homogeneous in terms of weight
or gestational age. Some studies included case histories that
occurred before the use of prenatal steroids or endotracheal
surfactants was widespread. Furthermore, in each study,
some patients in the control group were contaminated
(crossed-over) because they had received indomethacin
outside the limits of the study.5
Interestingly, some authors found that the timing of the first
dose of indomethacin was significantly associated with the
closure rate and that early administration reduced the need
for surgical ligation. Up to 85.2% of DAs closed if the first dose
of indomethacin was administered within 24 hours of birth;
however, this rate decreased to 48.1% when treatment was
started 72 hours or later after birth. The corresponding rates
for surgical ligation were 3.7% and 25.9%, respectively.49
In conclusion, various clinical trials have demonstrated
the effectiveness of indomethacin prophylaxis in closing
Botallo’s duct, but none have answered the fundamental
question of whether the prophylactic closure improved the
outcome. Prophylaxis does not appear to influence the
development of CLD, septicemia, ROP or mortality.
Although prophylaxis is associated with a reduction in
serious IVHs, an important predictor of long-term neurolo-
gical outcome, why prophylaxis does not influence long-
term neuromotor outcomes is not known.
In an observational study, a longer duration of indo-
methacin exposure was associated with less white matter
injury in infants delivered before 28 weeks of gestation.50
In a study by Madan,51 29% of 881 ELBW patients
received indomethacin prophylaxis within the first 24 hours
of life. The authors found that prophylaxis had no effect on
outcomes except for a borderline increase in NEC frequency
in those subjects who received prophylaxis and indometha-
cin therapy. In a recent study, the indomethacin prophylaxis
was directed by echocardiography.52
Recently, the prophylactic administration of indometha-
cin in extremely premature infants (i.e., those born between
23 and 24 weeks of gestation) decreased the incidence of
symptomatic PDA without increasing the incidence of
adverse effects.53
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In a study conducted in Asia, the incidence of IVH and
other episodes of bleeding were significantly higher than in
the controls, and the study was stopped early.54
Lower platelet counts have been associated with a higher
failure rate of indomethacin-induced PDA closure in human
newborns, which is pertinent to clinical practice.55
Additionally, administering cortisol to immature fetal
lambs in utero results in a ductus that responds to oxygen
and prostaglandin inhibition similar to that of a mature
fetus, which explains the decreased incidence of PDA in
preterm humans who are born to mothers who received
antenatal corticosteroids.56,14
Two commentary articles in the Journal of Pediatrics
emphasized that the consequences of treatment for PDA,
including the pharmacological side effects and surgery,
might be more harmful to the infant than the PDA itself.57,19
Moreover, there has been concern about the use of
NSAIDs and their long-term renal effects in ELBW infants.
In fact, ELBW infants treated with NSAIDs and aminoglyco-
sides have been found to have a renal volume less than the
10th percentile at 7 years of age in 40% of cases, which is
associated with a1 microglobinuria.58
Recently, Evans has adopted a new, targeted refinement
of prophylactic indomethacin, which consists of giving
indomethacin for early post-natal duct constriction assessed
echocardiographically. The author has also cited the
ongoing Australian DETECT trial, which includes infants
born before 29 weeks of gestation who, before being treated
(within the first 12 hours and, ideally, in the first 6 hours),
were examined using an echocardiogram to assess the duct
diameter. In this trial, preterm infants with well-constricted
ducts were not treated.59
PROPHYLACTIC USE OF IBUPROFEN
Preliminary experimental and clinical studies60,61 have
shown that ibuprofen, another cyclooxygenase inhibitor,
effectively closes the PDA without reducing the blood flow
to the brain 45,62 or influencing circulation in the intestines63
or kidneys.64
Van Overmeire performed a randomized, placebo-con-
trolled trial to determine whether ibuprofen could reduce
class III and IV IVH in patients with a gestational age of 24
to 30 weeks. This study showed that a significant reduction
in the incidence of PDA (16%) was associated with a lack of
differences in the primary outcome of serious IVH (ibupro-
fen does not reduce the frequency of IVH). Additionally, a
lack of differences was not seen in any secondary outcomes,
including mortality, PVL, combined CLD outcomes or death
at 36 weeks. In those receiving prophylaxis, there was a
significant increase in oliguria or an increase in creatinine
when compared with the group that did not receive
prophylactic treatment.65 A recent meta-analysis66 of pro-
phylactic ibuprofen for PDA showed a reduced incidence of
PDA, a reduced need for symptomatic treatment with
cyclooxygenase inhibitors and a reduced need for surgical
ligation. No advantage in the short-term outcomes was
demonstrated; no statistically significant difference in the
mortality or the incidence of BPD, NEC, gastrointestinal
hemorrhage, intestinal perforation, or ROP was demon-
strated between the ibuprofen-treated and placebo groups.
There was a statistically significant negative effect on kidney
function. In the control group, the PDA closed sponta-
neously by day three in 58% of the neonates.
Based on the current clinical data, there are no benefits
and possibly some harm with both the early use of
ibuprofen as either prophylaxis or treatment in the first
24 hours of life17,66 (e.g., pulmonary hypertension)67-69 and
prolonged courses of indomethacin (e.g., NEC).16
Ibuprofen therapy for PDA closure in preterm baboon
neonates was not associated with any increased risk of
neuropathology or alterations in brain growth and devel-
opment.70
Treatment with ibuprofen is safer than indomethacin
because there is a decreased risk of renal failure, thrombo-
cytopenia, and hyponatremia with ibuprofen.71
Renal safety should be emphasized because this is a major
consideration in choosing ibuprofen instead of indometha-
cin for early treatment.
There is sufficient evidence to suggest that ibuprofen, at
the currently proposed dosing regimen, has an efficacy
similar to that of indomethacin but is better tolerated by the
neonatal kidney when used to treat established PDA.72
This finding has been also observed in animals. In
suckling rats, indomethacin suppressed PGE2 and COX-2
expression and increased PGF2 expression, whereas ibu-
profen increased COX-2 and angiotensin II expression.
Although both NSAIDs suppressed 6-ketoPGF1 and TxB2
expression in suckling rats, the effect was sustained in
weanling rats with indomethacin. Thus, indomethacin
exhibits more potent suppressive effects on the expression
of renal COX-2 and vasodilator prostanoids, which are
important regulators of renal development and function.
These long-term, sustained effects may partly explain why
indomethacin has more severe adverse renal effects than
ibuprofen when administered early in postnatal life.73
Based on our personal experience,75-80 although ibuprofen
is less nephrotoxic than indomethacin, it may still have
adverse renal effects, even when administrated orally.73
These negative renal effects are only partially compensated
by the protection against oxidative stress.81
A recent paper by Vieux has confirmed our findings.82 They
found that ibuprofen-induced oligo-anuria is not associated
with a change in AQP2 activity and that ibuprofen does not
affect AQP2 activity during the first month of life in very
preterm neonates.83 This is in apparent contrast with the
findings from a long-term renal follow-up of premature
infants with and without perinatal indomethacin exposure. In
an older study,84 perinatal indomethacin did not affect long-
term renal growth, morphology or function in children born
before completing 33 weeks of gestation. However, in this
study, the duration of umbilical artery catheterization,
furosemide treatment and assisted ventilation were asso-
ciated with the later renal structural and functional anomalies.
Similar results have been obtained by other investigators.85
Therefore, prophylaxis unnecessarily exposes infants to a
drug with worrisome renal side effects without conferring
any significant short-term benefits. Prophylactic ibuprofen
treatment is not recommended.
Ibuprofen prophylaxis is associated with a higher
incidence of CLD. The conclusions to date do not support
the use of ibuprofen in PDA prophylaxis.17,66
PROPHYLACTIC SURGICAL LIGATION
The results of only one study that enrolled 84 ELBW infants
have been reported. The prophylactic group underwent ductal
ligation within 24 hours of life following a pre-specified
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protocol, whereas the control group received standard care
without indomethacin.86
Whereas prophylactic surgical ligation of the PDA did not
decrease mortality or BPD in ELBW infants, the incidence of
stage II and III NEC was significantly reduced. Based on the
current evidence, high rate of spontaneous closure, avail-
ability of effective safe medical therapies, and potential
short- and long-term complications of surgical ligation, the
use of prophylactic surgical ligation is not indicated.87
Recently, a re-examination of this controlled trial by the
authors found that prophylactic ligation significantly
increased the incidence of BPD (defined as a need for
supplemental oxygen at 36 weeks postmenstrual age) and
the incidence of mechanical ventilation at 36 weeks. These
findings suggest that although surgical prophylactic ductus
ligation eliminates the PDA, it may contribute to the
problem it is trying to prevent. Experimental studies have
been initiated to answer this question.88
Recently, in a study examining premature baboons versus
baboons with a persistent PDA, ibuprofen treatment had no
effect on the expression of genes that regulate pulmonary
inflammation but did increase the expression of alpha-
ENaC, the transepithelial sodium channel that is critical for
alveolar water clearance. Although ligation eliminates the
PDA, it does not improve pulmonary mechanics or increase
the alveolar surface area. In contrast with no intervention,
PDA ligation resulted in a significant increase in the
expression of genes associated with pulmonary inflamma-
tion (e.g., COX-2, TNF-alpha, and CD14) and a significant
decrease in alpha-ENaC expression. The authors speculated
that these changes may decrease the rate of alveolar fluid
clearance and contribute to the lack of improvement in
pulmonary mechanics following PDA ligation.89
The last report from the TIPP study reported that surgical
closure of a PDA reduced mortality to an almost significant
extent. However, neurosensory impairment was also sig-
nificantly increased by 18 months of age, as were retino-
pathy of prematurity and BPD.90 These findings are also
supported by others.91
Furthermore, it has been shown that there is a general
association between any surgery in the neonatal period and
neurosensory impairment at five years of age, indicating
that surgery and anesthesia might be independent risk
factors in VLBW infants.92
Bratlid recently confirmed that the surgical closure of a
patent DA in a small premature infant is associated with
neurosensory impairment.93
The following adverse events have been reported to
be associated with the surgical closure of PDA: recurrent
laryngeal nerve damage, chylothorax (thoracic duct injury),
pneumothorax, a period of left ventricular dysfunction
immediately after ligation, and the development of
scoliosis.94-98
Moreover, PDA ligation is sometimes associated with
impaired left ventricular systolic performance, which is
most likely attributable to altered loading conditions.
Neonates weighing 1,000 g or less are at an increased risk
of impaired left ventricular systolic performance, which is
probably due to maturational differences.99
Finally, it has very recently been confirmed that ligation
in preterm neonates has a considerable risk. Total mortality
in this vulnerable group of patients was 15%. Moreover,
severe complications and post-operative morbidity have
been reported.100
In conclusion, the current evidence does not support the
use of prophylactic surgical ligation of DAs in preterm
infants.101
However, it is vital for clinicians to understand the fluid
and cardiovascular changes that occur at birth and during
PDA management to gain a better appreciation of the
pathologic processes that may influence the clinical course
of an affected infant.102
FUTURE DIRECTIONS: THE IMPORTANCE OF
GENETIC FACTORS
It has been hypothesized that genetic factors play a
significant role in the pathophysiology of PDA.103
A retrospective study (1991–2006) from two centers was
performed using zygosity data from premature twins born
at 36 weeks of gestational age and surviving beyond 36
weeks of postmenstrual age.
Data from 333 dizygotic twin pairs and 99 monozygotic
twin pairs from two centers (Yale University and the
University of Connecticut) were obtained. The conclusion
was that preterm PDA is highly familial.103,104 While this is
the first study that formally isolated and quantified the overall
heritability, other studies have addressed the problem.
In a candidate gene study of 141 LBW newborns, Derzbach
et al.105 reported that boys with the ‘‘p’’ allele of the estrogen
receptor gene PvuII pP polymorphism were at a lower risk
for PDA but with a wide CI (OR: 0.24, 95% CI: 0.05–0.97).
In another candidate gene study of 153 LBW newborns,
Bokodi et al.106 showed that carriers of the interferon
gamma (+874) T allele were protected against PDA (OR:
0.43, 95% CI: 0.19–0.97) with a similarly wide CI.
Because approximately 30% of infants with PDA do not
respond to pharmacologic treatments for closure, some
authors have investigated whether single nucleotide poly-
morphisms (SNPs) in genes that regulate smooth muscle
contraction, xenobiotic detoxification, inflammation or other
processes are markers for the persistent patency of the DA.
Initially, 377 SNPs from 130 genes of interest were evaluated
in DNA samples collected from 204 infants with a
gestational age of less than 32 weeks.
SNPs in the AP-2 beta (TFAP2B) and TNF receptor-
associated factor 1 (TRAF1) genes remained significant, both
with p-values of 0.005. These data support a genetic
contribution to the risk of PDA in preterm infants.107
Genetic polymorphisms in the cytochrome P450 (CYP)
family of enzymes can contribute to the pharmacokinetic
(PK) variability of drugs. PK variability is observed as a
bimodal distribution of extensive metabolizers (EMs) and
poor metabolizers (PMs). PK variability may also exist
between individuals genotyped as homozygous EMs and
heterozygous EMs. This can have implications for drug
dosing and the drug response (e.g., the risk of therapeutic
failure or drug toxicity), especially for NSAIDs.108
However, CYP2C8 and 2C9 polymorphisms do not appear
to be involved in the response of preterm infants to ibuprofen
therapy for PDA and cannot be used to optimize the ductal
closure rate by modulating the ibuprofen-dosing strategy.109
In contrast, this study reported the role of ethnicity in the
interindividual variability of the response to ibuprofen and
subsequent PDA closure in preterm infants. Interethnic
differences in the neonatal PDA clinical course should be
further explored and correlated to ibuprofen pharmacoki-
netics.109 Additionally, recent studies have reported that three
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independent risk factors (immature gestation, the absence of
antenatal glucocorticoid exposure, and the presence of the
rs2817399(A) allele of the gene, TFAP2B) are associated with
DAs that fail to close with prostaglandin inhibition.
Furthermore, these risk factors affected a common set of
genes that increase the risk of persistent PDA after birth. In a
study examining the ductus in term, preterm, and glucocorti-
coid-treated preterm baboon fetuses, it was found that both
immature birth and the absence of antenatal glucocorticoids
decreased the RNA expression of the calcium- and potassium-
channel genes involved in oxygen-induced constriction and
phosphodiesterase genes, which modulate cAMP/cGMP
signaling. Furthermore, in a study in which ductus obtained
from second trimester human pregnancies were genotyped
for TFAP2B polymorphisms, when present, the rs2817399(A)
allele was also associated with the decreased expression of
calcium- and potassium-channel genes. In contrast, alleles of
two other TFAP2B polymorphisms, rs2817419(G) and
rs2635727(T), were not correlated with the incidence of PDA
after birth and had no effect on RNA expression. Three
calcium- and potassium-channel genes (CACNA1G/
alpha1G, CACNB 2/CaL-beta2, and KCNA2/Kv1.2) were
similarly affected by each of the risk factors associated with
PDA. The authors speculated that these channels may play a
significant role in closing the preterm ductus following
prostaglandin inhibition and may be potential targets for
future pharmacologic manipulations.110
Therefore, knowing the genes responsible for maintaining
the balance between patency and closure and the related
epigenetic factors is an important step toward developing
pharmacogenetic strategies tailored to individual genomes.
A better understanding of the genetic background of this
developmental process can help develop new strategies to
manipulate the DA in premature infants, neonates with
duct-dependent cardiac anomalies, and patients with
syndromic and non-syndromic PDA.104 The practical
message is that, if these data are true, we must individualize
NSAID treatment and prophylaxis.112 Metabolomics may
provide the answer to this question.112,113 In fact, a
metabolic signature for PDA in preterm infants has been
identified using an NMR-based metabolomic analysis of
urine.113 By collecting the first urine at birth, it is possible to
anticipate the persistence of PDA at day 4.
CONCLUSIONS
There has been much debate in recent years as to when a
PDA is pathologic and when closure is indicated. There is a
pressing need to better understand the benefits and risks of
all PDA treatments.114-122
Currently, it is unclear whether and when a conservative,
pharmacologic or surgical approach for PDA closure may
be advantageous,13 and this is also the opinion of the
authors.118,119
Based on the current literature, we can offer some
suggestions regarding prophylaxis.
Al Faleh, who supports the prophylactic use of indo-
methacin, has recently hypothesized that the results of the
TIPP study were influenced by fluid overload and pulmon-
ary edema. In his opinion, fluid restriction might decrease
the rate of BPD in ELBW infants who receive indomethacin
prophylaxis.120
Prophylaxis with ibuprofen cannot be recommended, as it
does not prevent IVH; it is important to avoid ibuprofen in
infants in whom the DA may spontaneously close. Routine
prophylaxis with indomethacin cannot be recommended for
the prevention of long-term morbidities and mortality,
especially in centers where severe IVH is comparable to the
national average and surgical complications are minimal.120
Table 1 presents ten reasons for definitively abandoning
PDA prophylaxis.
In conclusion, because they expose a significant number
of preterm infants who will never develop PDA (40–60%) to
potential severe, drug-related complications, all types of
PDA prophylaxis, including indomethacin, cannot be
considered a ‘standard of care’ until their long-term efficacy
is proven in clinical trials.
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